
Dutch biotech company Targed Biopharmaceuticals has evidently drawn attention to its treatment approach for blood-clotting disorders, also known as thrombotic diseases, as an investor syndicate has just injected EUR 39m into the company.
The syndicate included venture capital firm Sunstone Life Science Ventures, Norwegian Hadean Ventures, Andera Partners, Fund+ and Inkef Capital in addition to three existing investors in Targed Biopharma, which was founded in 2020 as a spinout from the University Medical Center Utrecht.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app